Physician profile
Muhammad Ali Ehtesham
NPI 1881625960
$21,014.74
in general payments reported to CMS, 2019-2025
41 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,017 · 2020: $1,679 · 2021: $1,209 · 2022: $1,832 · 2023: $2,220 · 2024: $1,836 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,565 · Consulting Fee: $4,669 · Travel and Lodging: $2,709 · Education: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,565.05 |
| Consulting Fee | $4,668.75 |
| Travel and Lodging | $2,708.82 |
| Education | $335.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,823.79 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $2,863.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $895.86 | 2020-2025 | Airsupra, Tezspire, Fasenra |
| United Therapeutics Corporation | $882.69 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Veran Medical Technologies, INC. | $776.62 | 2020 | |
| Genzyme Corporation | $754.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $674.10 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $595.93 | 2019-2024 | Yupelri |
| Baxter Healthcare | $566.00 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $473.89 | 2019-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $336.73 | 2019-2020 | |
| Pulmonx Corporation | $335.05 | 2020-2025 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Actelion Pharmaceuticals US, INC. | $324.76 | 2019-2023 | Opsumit, Uptravi |
| Insmed, INC. | $307.72 | 2019-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $211.50 | 2024-2025 | Acthar |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $200.96 | 2021-2025 | |
| Philips North America LLC | $182.11 | 2020-2025 | Vest Therapy Und, (8874) Incourage, Incourage Airway Clearance Therapy |
| Mallinckrodt Enterprises LLC | $177.37 | 2019 | |
| Electromed, INC. | $166.85 | 2022-2025 | Smartvest |
| Csl Behring | $162.22 | 2019-2024 | Kcentra |
| Advanced Respiratory, INC | $133.36 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $130.67 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $128.81 | 2019-2025 | Keytruda, Winrevair |
| Inspire Medical Systems, INC. | $110.94 | 2024 | Inspire |
| Amgen INC. | $98.14 | 2022-2025 | Tezspire |
| Bard Access Systems, INC. | $93.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $88.99 | 2023 | |
| Axsome Therapeutics, INC. | $62.34 | 2025 | Sunosi |
| Gilead Sciences, INC. | $54.49 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.65 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.84 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.81 | 2021 | |
| Circassia INC. | $47.99 | 2019 | |
| Lilly USA, LLC | $43.87 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $34.31 | 2025 | Purified Cortrophin Gel |
| Lungpacer Medical USA INC | $30.39 | 2025 | Aeropace Neurostimulation Console |
| Pfizer INC. | $21.89 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $21.59 | 2024 | Lumryz |
| Covis Pharma Gmbh | $17.24 | 2022 | |
| Genentech USA, INC. | $15.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ehtesham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.